Table 3.

Overall survival by donor/recipient Bw4 status and Bw4 ligand strength in the UNOS cohort.

Donor	Recipient	Inhibition	Licensing	N	Events	Median Survival (years +/− 95% CI)		Mortality hazard ratio (+/− 95% CI)		P-value
Bw6/Bw6	Bw4+	−	+	2919	1780	6.96	6.59 – 7.26	1
Bw4+	Bw4+	+	+	4891	3112	6.59	6.37 – 6.86	1.07	1.01 – 1.13	0.03*
Bw4+	Bw6/Bw6	+	−	3045	1986	6.38	6.08 – 6.70	1.11	1.05 – 1.19	<0.001***
Bw6/Bw6	Bw6/Bw6	−	−	1990	1273	6.49	6.14 – 6.82	1.09	1.01 – 1.17	0.02*
Donor	Recipient	Inhibition	Licensing	N		Median Survival (years +/− 95% CI)		Mortality hazard ratio (+/− 95% CI)		P-value
Bw6/Bw6	Bw4+	−	+	2919	1780	6.96	6.59 – 7.26	1
Bw4-80T+	Bw4+	+	+	2272	1453	6.70	6.38 – 7.10	1.05	0.98 – 1.13	0.14
Bw4-80I+	Bw4+	++	+	2619	1659	6.48	6.16 – 6.84	1.08	1.01 – 1.15	0.03*
Bw6/Bw6	Bw4+	−	+	2919	1780	6.96	6.59 – 7.26	1
Bw4/Bw6	Bw4+	+	+	3777	2385	6.69	6.47 – 7.04	1.05	0.98 – 1.11	0.15
Bw4/Bw4	Bw4+	++	+	1114	727	6.04	5.60 – 6.71	1.14	1.04 – 1.24	0.004**
Bw6/Bw6	Bw6	−	−	1990	1273	6.49	6.14 – 6.82	1
Bw6/Bw6	Bw4-80T+	−	+	1540	939	7.16	6.69 – 7.63	0.89	0.82 – 0.97	0.007**
Bw6/Bw6	Bw4-80I+	−	++	1379	841	6.73	6.17 – 7.13	0.96	0.88 – 1.04	0.32
Bw6/Bw6	Bw6/Bw6	−	−	1990	1273	6.49	6.14 – 6.82	1
Bw6/Bw6	Bw4/Bw6	−	+	2264	1377	7.00	6.60 – 7.38	0.91	0.84 – 0.98	0.02*
Bw6/Bw6	Bw4/Bw4	−	++	655	403	6.70	6.13 – 7.41	0.95	0.85 –1.07	0.41